TMEM173 Antibody - middle region : FITC (ARP48041_P050-FITC)

TMEM173 acts as a facilitator of innate immune signaling. It is able to activate both NF-kappa-B and IRF3 transcription pathways to induce expression of type I interferon (IFN-alpha and IFN-beta) and exert a potent anti-viral state following expression. TMEM173 may be involved in translocon function, the translocon possibly being able to influence the induction of type I interferons.It also may be involved in transduction of apoptotic signals via its association with the major histocompatibility complex class II (MHC-II) . TMEM173 mediates death signaling via activation of the extracellular signal-regulated kinase (ERK) pathway.

MAVS; TBK1; UBC; TRAF3; IRF3; TOMM70A; TSPAN6; TRIM32; STT3B; TMEM259; YIPF5; HM13; CLPTM1L; MBOAT7; CCDC47; SEC61A1; CNNM3; LTN1; SLC39A14; GLMN; SGPL1; SURF4; RNF5; ABCC1; STT3A; IRAK1; ACSL3; DDOST; NPC1; TMEM173; TRIM56

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.